☰

Deborah A. Berg, Ph.D. - Publications

Affiliations: 
2000 Cleveland State University, Cleveland, OH, United States 
Area:
Guidance and Counseling Education, Educational Psychology Education, Clinical Psychology
Tree Info Similar researchers PubMed Report error

0/55 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
Low-probability matches (unlikely to be authored by this person)
2024 McDonnell SRP, Nguyen VA, Walton NM, Merkwirth C, Hong F, Berg D, Muensterman ET, Furie RA. Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus Science & Medicine. 11. PMID 38453421 DOI: 10.1136/lupus-2023-001112  0.01
2021 Iida S, Izumi T, Komeno T, Terui Y, Chou T, Ikeda T, Berg D, Fukunaga S, Sugiura K, Sasaki M. A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma. International Journal of Clinical Oncology. PMID 34599726 DOI: 10.1007/s10147-021-02030-7  0.01
2021 Dispenzieri A, Kastritis E, Wechalekar AD, Schönland SO, Kim K, Sanchorawala V, Landau HJ, Kwok F, Suzuki K, Comenzo RL, Berg D, Liu G, Kumar A, Faller DV, Merlini G. A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. Leukemia. PMID 34168284 DOI: 10.1038/s41375-021-01317-y  0.01
2021 Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Gimsing P, Garderet L, Touzeau C, ... ... Berg D, et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100972. PMID 34111952 DOI: 10.1200/JCO.21.00972  0.01
2020 Bond AM, Berg DA, Lee S, Garcia-Epelboim AS, Adusumilli VS, Ming GL, Song H. Differential Timing and Coordination of Neurogenesis and Astrogenesis in Developing Mouse Hippocampal Subregions. Brain Sciences. 10. PMID 33255945 DOI: 10.3390/brainsci10120909  0.01
2020 Dash AB, Zhang J, Shen L, Li B, Berg D, Lin J, Avet-Loiseau H, Bahlis NJ, Moreau P, Richardson PG, Di Bacco A. Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation. European Journal of Haematology. PMID 32350909 DOI: 10.1111/ejh.13435  0.01
2020 Di Bacco A, Bahlis NJ, Munshi NC, Avet-Loiseau H, Masszi T, Viterbo L, Pour L, Ganly P, Cavo M, Langer C, Kumar SK, Rajkumar SV, Keats JJ, Berg D, Lin J, et al. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. European Journal of Haematology. PMID 32145111 DOI: 10.1111/Ejh.13405  0.01
2019 Dimopoulos MA, Laubach JP, Echeveste Gutierrez MA, Grzasko N, Hofmeister CC, San-Miguel JF, Kumar S, Labotka R, Lu V, Berg D, Byrne C, Teng Z, Liu G, van de Velde H, Richardson PG. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. European Journal of Haematology. PMID 30943323 DOI: 10.1111/ejh.13231  0.01
2019 Berg DA, Su Y, Jimenez-Cyrus D, Patel A, Huang N, Morizet D, Lee S, Shah R, Ringeling FR, Jain R, Epstein JA, Wu QF, Canzar S, Ming GL, Song H, et al. A Common Embryonic Origin of Stem Cells Drives Developmental and Adult Neurogenesis. Cell. PMID 30929900 DOI: 10.1016/J.Cell.2019.02.010  0.01
2019 Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. PMID 30696949 DOI: 10.1038/S41375-019-0384-1  0.01
2018 Iida S, Izumi T, Aotsuka N, Komeno T, Ishida T, Sunami K, Handa H, Berg D, Kase Y, Soeda J. [Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma]. [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology. 59: 2399-2407. PMID 30531133 DOI: 10.11406/rinketsu.59.2399  0.01
2018 Richardson PG, Hofmeister CC, Rosenbaum CA, Htut M, Vesole DH, Berdeja JG, Liedtke M, Chari A, Smith SD, Lebovic D, Raje N, Byrne C, Liao E, Gupta N, Bacco AD, ... ... Berg D, et al. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. British Journal of Haematology. PMID 29938772 DOI: 10.1111/bjh.15394  0.01
2018 Hari P, Lin HM, Zhu Y, Berg D, Richardson PG, Moreau P. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. Journal of Medical Economics. 1-15. PMID 29741409 DOI: 10.1080/13696998.2018.1474745  0.01
2018 Leleu X, Masszi T, Bahlis NJ, Viterbo L, Baker B, Gimsing P, Maisnar V, Samoilova O, Rosiñol L, Langer C, Song K, Izumi T, Cleeland C, Berg D, Lin HM, et al. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. American Journal of Hematology. PMID 29726031 DOI: 10.1002/ajh.25134  0.01
2018 Berg DA, Bond AM, Ming GL, Song H. Radial glial cells in the adult dentate gyrus: what are they and where do they come from? F1000research. 7: 277. PMID 29568500 DOI: 10.12688/F1000Research.12684.1  0.01
2018 Garderet L, Laubach JP, Stoppa AM, Hari P, Cavo M, Ludwig H, Mateos MV, Luptakova K, Lin J, Yung G, van de Velde H, Berg D, Moreau P, Richardson PG. Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. Leukemia. PMID 29568098 DOI: 10.1038/s41375-018-0091-3  0.01
2018 Gupta N, Hanley MJ, Diderichsen PM, Yang H, Ke A, Teng Z, Labotka R, Berg D, Patel C, Liu G, van de Velde H, Venkatakrishnan K. Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor. Clinical Pharmacology and Therapeutics. PMID 29446068 DOI: 10.1002/cpt.1047  0.01
2017 Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, ... ... Berg D, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. PMID 29054911 DOI: 10.1182/Blood-2017-06-791228  0.01
2017 Richardson PG, Kumar S, Laubach JP, Paba-Prada C, Gupta N, Berg D, van de Velde H, Moreau P. New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. Journal of Blood Medicine. 8: 107-121. PMID 28860887 DOI: 10.2147/JBM.S102328  0.01
2017 Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, et al. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. PMID 28751562 DOI: 10.3324/haematol.2017.170118  0.01
2017 Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory light-chain (AL) amyloidosis. Blood. PMID 28550039 DOI: 10.1182/Blood-2017-03-771220  0.01
2017 Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, ... Berg D, et al. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. British Journal of Haematology. PMID 28485007 DOI: 10.1111/bjh.14733  0.01
2017 Kumar SK, Vij R, Noga SJ, Berg D, Brent L, Dollar L, Chari A. Treating Multiple Myeloma Patients With Oral Therapies. Clinical Lymphoma, Myeloma & Leukemia. PMID 28347676 DOI: 10.1016/j.clml.2017.02.024  0.01
2017 Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, Venkatakrishnan K. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. Clinical Pharmacokinetics. PMID 28290121 DOI: 10.1007/s40262-017-0526-4  0.01
2017 Lin HM, Gao X, Cooke CE, Berg D, Labotka R, Faller DV, Seal B, Hari P. Disease burden of systemic light-chain (AL) amyloidosis: a systematic literature review. Current Medical Research and Opinion. 1-34. PMID 28277869 DOI: 10.1080/03007995.2017.1297930  0.01
2016 Kang E, Berg DA, Furmanski O, Jackson WM, Ryu YK, Gray CD, Mintz CD. Neurogenesis and developmental anesthetic neurotoxicity. Neurotoxicology and Teratology. PMID 27751818 DOI: 10.1016/J.Ntt.2016.10.001  0.01
2016 Qian X, Nguyen HN, Song MM, Hadiono C, Ogden SC, Hammack C, Yao B, Hamersky GR, Jacob F, Zhong C, Yoon KJ, Jeang W, Lin L, Li Y, Thakor J, ... Berg DA, et al. Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure. Cell. PMID 27118425 DOI: 10.1016/J.Cell.2016.04.032  0.01
2016 Bonaguidi MA, Stadel RP, Berg DA, Sun J, Ming GL, Song H. Diversity of Neural Precursors in the Adult Mammalian Brain. Cold Spring Harbor Perspectives in Biology. PMID 26988967 DOI: 10.1101/Cshperspect.A018838  0.01
2015 Lin HM, Seldin D, Hui AM, Berg D, Dietrich CN, Flood E. The patient's perspective on the symptom and everyday life impact of AL amyloidosis. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 1-8. PMID 26587688 DOI: 10.3109/13506129.2015.1102131  0.01
2015 Hameed LS, Berg DA, Belnoue L, Jensen LD, Cao Y, Simon A. Environmental changes in oxygen tension reveal ROS-dependent neurogenesis and regeneration in the adult newt brain. Elife. 4. PMID 26485032 DOI: 10.7554/Elife.08422  0.01
2015 Shin J, Berg DA, Zhu Y, Shin JY, Song J, Bonaguidi MA, Enikolopov G, Nauen DW, Christian KM, Ming GL, Song H. Single-Cell RNA-Seq with Waterfall Reveals Molecular Cascades underlying Adult Neurogenesis. Cell Stem Cell. 17: 360-72. PMID 26299571 DOI: 10.1016/J.Stem.2015.07.013  0.01
2015 Smith DC, Kalebic T, Infante JR, Siu LL, Sullivan D, Vlahovic G, Kauh JS, Gao F, Berger AJ, Tirrell S, Gupta N, Di Bacco A, Berg D, Liu G, Lin J, et al. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Investigational New Drugs. 33: 652-63. PMID 25777468 DOI: 10.1007/s10637-015-0230-x  0.01
2015 Hameed LS, Berg DA, Belnoue L, Jensen LD, Cao Y, Simon A. Author response: Environmental changes in oxygen tension reveal ROS-dependent neurogenesis and regeneration in the adult newt brain Elife. DOI: 10.7554/Elife.08422.022  0.01
2015 Berg DA, Yoon KJ, Will B, Xiao AY, Kim NS, Christian KM, Song H, Ming Gl. Tbr2-expressing intermediate progenitor cells in the adult mouse hippocampus are unipotent neuronal precursors with limited amplification capacity under homeostasis Frontiers in Biology. 10: 262-271. DOI: 10.1007/S11515-015-1364-0  0.01
2014 Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. The Lancet. Oncology. 15: 1503-12. PMID 25456369 DOI: 10.1016/S1470-2045(14)71125-8  0.01
2014 Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 124: 1038-46. PMID 24920586 DOI: 10.1182/blood-2014-01-548826  0.01
2014 Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A, Yu J, Shou Y, Niesvizky R. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 124: 1047-55. PMID 24904120 DOI: 10.1182/blood-2014-01-548941  0.01
2014 Kirkham M, Hameed LS, Berg DA, Wang H, Simon A. Progenitor cell dynamics in the Newt Telencephalon during homeostasis and neuronal regeneration. Stem Cell Reports. 2: 507-19. PMID 24749074 DOI: 10.1016/J.Stemcr.2014.01.018  0.01
2013 Bak Y, Merriam M, Neff M, Berg DA. Novel approach to rectal foreign body extraction. Jsls : Journal of the Society of Laparoendoscopic Surgeons / Society of Laparoendoscopic Surgeons. 17: 342-5. PMID 23925034 DOI: 10.4293/108680813X13654754534233  0.01
2013 Berg DA, Belnoue L, Song H, Simon A. Neurotransmitter-mediated control of neurogenesis in the adult vertebrate brain. Development (Cambridge, England). 140: 2548-61. PMID 23715548 DOI: 10.1242/Dev.088005  0.01
2011 Kirkham M, Berg DA, Simon A. Microglia activation during neuroregeneration in the adult vertebrate brain. Neuroscience Letters. 497: 11-6. PMID 21515337 DOI: 10.1016/J.Neulet.2011.04.007  0.01
2011 Berg DA, Kirkham M, Wang H, Frisén J, Simon A. Dopamine controls neurogenesis in the adult salamander midbrain in homeostasis and during regeneration of dopamine neurons. Cell Stem Cell. 8: 426-33. PMID 21474106 DOI: 10.1016/J.Stem.2011.02.001  0.01
2011 Berg DA, Kirkham M, Beljajeva A, Knapp D, Habermann B, Ryge J, Tanaka EM, Simon A. Erratum: Efficient regeneration by activation of neurogenesis in homeostatically quiescent regions of the adult vertebrate brain (Development 137 (4127-4134)) Development. 138. DOI: 10.1242/Dev.061754  0.01
2010 Berg DA, Kirkham M, Beljajeva A, Knapp D, Habermann B, Ryge J, Tanaka EM, Simon A. Efficient regeneration by activation of neurogenesis in homeostatically quiescent regions of the adult vertebrate brain. Development (Cambridge, England). 137: 4127-34. PMID 21068061 DOI: 10.1242/Dev.055541  0.01
2010 Thompson GR, Patel PK, Kirkpatrick WR, Westbrook SD, Berg D, Erlandsen J, Redding SW, Patterson TF. Oropharyngeal candidiasis in the era of antiretroviral therapy Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology. 109: 488-495. PMID 20156694 DOI: 10.1016/j.tripleo.2009.11.026  0.01
2009 Simon A, Berg D, Kirkham M. Not lost in translation Sensing the loss and filling the gap during regeneration. Seminars in Cell & Developmental Biology. 20: 691-6. PMID 19463964 DOI: 10.1016/J.Semcdb.2009.04.015  0.01
2007 Berg DA, Milner RE, Fisher CA, Goldberg AJ, Dempsey DT, Grewal H. A cost-effective approach to establishing a surgical skills laboratory. Surgery. 142: 712-21. PMID 17981192 DOI: 10.1016/j.surg.2007.05.011  0.01
2007 Monroy MA, Opperman KK, Pucciarelli M, Yerrum S, Berg DA, Daly JM. THE PPARgamma ligand 15d-PGJ2 modulates macrophage activation after injury in a murine trauma model. Shock (Augusta, Ga.). 28: 186-91. PMID 17510607 DOI: 10.1097/shk.0b013e3180310982  0.01
2006 Smith EL, Skosey C, Armer J, Berg D, Cirrincione C, Henggeler M. The cancer and leukemia group B oncology nursing committee (1983-2006): a history of passion, commitment, challenge, and accomplishment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3638s-41s. PMID 16740799 DOI: 10.1158/1078-0432.Ccr-06-9013  0.01
2006 Berg DA, Tynan MG, Grewal H. Magnets in the stomach. Journal of Pediatric Surgery. 41: 1037-9. PMID 16677908 DOI: 10.1016/j.jpedsurg.2005.12.053  0.01
2005 Berg DA, Milner RE, Demangone D, Ufberg JW, McKernan E, Fisher CA, Gaughan JP, Grewal H, Dempsey DT, Goldberg AJ. Successful collaborative model for trauma skills training of surgical and emergency medicine residents in a laboratory setting. Current Surgery. 62: 657-62, discussion 6. PMID 16293506 DOI: 10.1016/j.cursur.2005.08.006  0.01
2005 Anstead GM, Corcoran G, Lewis J, Berg D, Graybill JR. Refractory coccidioidomycosis treated with posaconazole Clinical Infectious Diseases. 40: 1770-1776. PMID 15909265 DOI: 10.1086/430303  0.01
2003 Berg D. Oxaliplatin: a novel platinum analog with activity in colorectal cancer. Oncology Nursing Forum. 30: 957-66. PMID 14603353 DOI: 10.1188/03.ONF.957-966  0.01
1992 Berg DA, Menino AR. Bovine embryos produce a urokinase-type plasminogen activator. Molecular Reproduction and Development. 31: 14-9. PMID 1562322 DOI: 10.1002/mrd.1080310104  0.01
1955 PIOTROWSKI ZA, BERG DA. Verification of the Rorschach alpha diagnostic formula for underactive schizophrenics. The American Journal of Psychiatry. 112: 443-50. PMID 13275592  0.01
Hide low-probability matches.